<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04313335</url>
  </required_header>
  <id_info>
    <org_study_id>KY 2020-009-02</org_study_id>
    <nct_id>NCT04313335</nct_id>
  </id_info>
  <brief_title>Duloxetine for PHN</brief_title>
  <official_title>Prophylactic Duloxetine Administration During Acute Herpes Zoster Prevents Postherpetic Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Second Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taiyuan Central Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linfen Fourth People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao Municipal Hospital (Group)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huai'an Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cangzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The People's Hospital of Fujian Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tsinghua Chang Gung Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University International Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin First Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Huanhu Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baoding First Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators aim to investigate the preventive efficacy of prophylactic
      oral duloxetine during acute herpes zoster on postherpetic neuralgia and its safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postherpetic neuralgia is a common complication of herpes zoster. Several interventions have
      been investigated for the treatment of postherpetic neuralgia, however, there is a lack of
      preventive intervention on postherpetic neuralgia. A recent retrospective study revealed that
      the administration of gabapentin during the acute herpes zoster period significantly
      decreased the incidence of postherpetic neuralgia. In the present study, the investigators
      aim to conduct a prospective, randomized, open-label, endpoint blinded study to investigate
      the preventive efficacy of prophylactic use of duloxetine on postherpetic neuralgia.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The outcome of the study will be assessed by a third-party organization who will be blinded to the study allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Preventive efficacy of Postherpetic neuralgia</measure>
    <time_frame>12 weeks after the reactivation of acute herpes zoster</time_frame>
    <description>The proportion of participants in the Interventional Arm who gain a 0 score in a 100 mm visual analgue scale (0 mm = no pain, 100 mm = the most imaginable pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Averaged weekly VAS score</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Averaged weekly VAS score of each participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Averaged weekly analgesic consumption</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Averaged weekly consumption per analgesic of each participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' overall quality of life</measure>
    <time_frame>At the end of Weeks 4, 8, and 12</time_frame>
    <description>12-item Short-Form Health Survey (SF-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>At the end of Weeks 4, 8, and 12</time_frame>
    <description>Pittsburgh Sleep Quality Index (PSQI) self-rated questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Postherpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apart from the standard treatment, participants in the Duloxetine Arm will be administered with oral duloxetine (up to 60 mg per day) in the acute herpes zoster period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will be given the standard treatment during the acute herpes zoster period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Oral Duloxetine (up to 60 mg per day) will be given, titrated, tapered in accordance with the pain intensity during the acute herpes zoster period.</description>
    <arm_group_label>Duloxetine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages more than 50 years;

          -  diagnosed with uncomplicated acute herpes zoster;

          -  presents with vesicles within 72 hours;

          -  has an average pain score of at least 40/100 mm on a visual analog scale (VAS, 0 = no
             pain, 100 = worst possible pain, at opposite ends of a 100-mm line).

        Exclusion Criteria:

          -  refuses to participate or to provide written informed consent;

          -  Zung Self-Rating Depression Scale raw score of more than 50 points;

          -  herpes zoster that involves with head, neck, ocular, mucous membrane, cranial nerve,
             or central nervous system;

          -  has hemorrhagic or necrotizing lesions, satellite lesions, abnormal vesicles or acute
             retinal necrosis;

          -  has been on immunosuppressive therapy or mono- or multi-pharmacotherapy that involves
             any tricyclic antidepressant, valacyclovir, duloxetine or cytotoxic medications before
             acute HZ onset;

          -  has been diagnosed with hepatic, renal or immune dysfunction;

          -  during pregnancy or breastfeeding at the time;

          -  hypersensitivity to the study drugs;

          -  has contraindications to valacyclovir or duloxetine;

          -  HZ vaccinated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fang Luo, M.D.</last_name>
    <phone>+86 13611326978</phone>
    <email>13611326978@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, Patrick D, Camden S, Mansi JA. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain. 2010 Nov;11(11):1211-21. doi: 10.1016/j.jpain.2010.02.020.</citation>
    <PMID>20434957</PMID>
  </reference>
  <reference>
    <citation>Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014 Oct 16;371(16):1526-33. doi: 10.1056/NEJMcp1403062. Review.</citation>
    <PMID>25317872</PMID>
  </reference>
  <reference>
    <citation>Schutzer-Weissmann J, Farquhar-Smith P. Post-herpetic neuralgia - a review of current management and future directions. Expert Opin Pharmacother. 2017 Nov;18(16):1739-1750. doi: 10.1080/14656566.2017.1392508. Epub 2017 Oct 26. Review.</citation>
    <PMID>29025327</PMID>
  </reference>
  <reference>
    <citation>Bulilete O, Leiva A, Rullán M, Roca A, Llobera J; PHN Group. Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: A double blind, randomized controlled trial. PLoS One. 2019 Jun 5;14(6):e0217335. doi: 10.1371/journal.pone.0217335. eCollection 2019.</citation>
    <PMID>31166976</PMID>
  </reference>
  <reference>
    <citation>Ghanavatian S, Wie CS, Low RS, Zhang N, Montoya JM, Dhaliwal GS, Swanson DL. Premedication With Gabapentin Significantly Reduces the Risk of Postherpetic Neuralgia in Patients With Neuropathy. Mayo Clin Proc. 2019 Mar;94(3):484-489. doi: 10.1016/j.mayocp.2018.11.004. Epub 2019 Feb 2.</citation>
    <PMID>30718068</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 7, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Fang Luo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Postherpetic Neuralgia, Duloxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

